Cargando…

Outbreak of infections with the COVID-19 virus mutation B.1.351 about four weeks after the second successful vaccination with BNT162b2

Detalles Bibliográficos
Autores principales:	Ortloff, Andrea, Harsch, Igor Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	German Medical Science GMS Publishing House 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165486/ https://www.ncbi.nlm.nih.gov/pubmed/34123704 http://dx.doi.org/10.3205/dgkh000387

Ejemplares similares

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants
por: Abu-Raddad, Laith J., et al.
Publicado: (2021)

Impact of BNT162b first vaccination on the immune transcriptome of elderly patients infected with the B.1.351 SARS-CoV-2 variant
por: Knabl, Ludwig, et al.
Publicado: (2021)

Impact of BNT162b First Vaccination on the Immune Transcriptome of Elderly Patients Infected with the B.1.351 SARS-CoV-2 Variant
por: Knabl, Ludwig, et al.
Publicado: (2021)

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination
por: Wall, Emma C, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
por: Shen, Xiaoying, et al.
Publicado: (2021)

Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants
por: Zani, Alberto, et al.
Publicado: (2021)

COVID-19 rise in Bangladesh correlates with increasing detection of B.1.351 variant
por: Saha, Senjuti, et al.
Publicado: (2021)

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
por: Martinez, David R., et al.
Publicado: (2021)

Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
por: Martinez, David R., et al.
Publicado: (2021)

The SARS-CoV-2 B.1.351 Variant Can Transmit in Rats But Not in Mice
por: Zhang, Cheng, et al.
Publicado: (2022)

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7
por: Wang, Pengfei, et al.
Publicado: (2021)

Case series of four re-infections with a SARS-CoV-2 B.1.351 variant, Luxembourg, February 2021
por: Staub, Thérèse, et al.
Publicado: (2021)

The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus
por: Kim, Yeong Jun, et al.
Publicado: (2021)

Detection of B.1.351 SARS-CoV-2 Variant Strain — Zambia, December 2020
por: Mwenda, Mulenga, et al.
Publicado: (2021)

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
por: Shinde, Vivek, et al.
Publicado: (2021)

Effects of B.1.1.7 and B.1.351 on COVID-19 Dynamics: A Campus Reopening Study
por: Linka, Kevin, et al.
Publicado: (2021)

Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant Beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study
por: Singer, Shepherd R., et al.
Publicado: (2021)

Increased Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to Antibody Neutralization
por: Wang, Pengfei, et al.
Publicado: (2021)

COVID-19 outbreak trends in South Africa: A comparison of Omicron (B.1.1.529), Delta (B.1.617.2), and Beta (B.1.351) variants outbreak periods
por: Al Hasan, Syed Mahfuz, et al.
Publicado: (2022)

Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant
por: Edara, Venkata Viswanadh, et al.
Publicado: (2021)

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
por: Hoffmann, Markus, et al.
Publicado: (2021)

The Infection and Pathogenicity of SARS-CoV-2 Variant B.1.351 in hACE2 Mice
por: Chen, Qi, et al.
Publicado: (2021)

Linked Clusters of SARS-CoV-2 Variant B.1.351 — Maryland, January–February 2021
por: Feder, Kenneth A., et al.
Publicado: (2021)

Early detection of community acquired of SARS-CoV-2 lineage B.1.351 in Hong Kong
por: Tsang, Alan K.L., et al.
Publicado: (2021)

Infection with the SARS-CoV-2 B.1.351 variant is lethal in aged BALB/c mice
por: Yasui, Fumihiko, et al.
Publicado: (2022)

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine
por: Dayan, Gustavo H., et al.
Publicado: (2023)

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera
por: Zhou, Daming, et al.
Publicado: (2021)

Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
por: Yu, Jingyou, et al.
Publicado: (2021)

Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques
por: Munster, Vincent J., et al.
Publicado: (2021)

Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques
por: Munster, Vincent J., et al.
Publicado: (2021)

SARS-CoV-2 501Y.V2 (B.1.351) elicits cross-reactive neutralizing antibodies
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Functional Effects of Receptor-Binding Domain Mutations of SARS-CoV-2 B.1.351 and P.1 Variants
por: Bayarri-Olmos, Rafael, et al.
Publicado: (2021)

Seroprevalence of SARS-CoV-2 infection in the Tyrolean district of Schwaz at the time of the rapid mass vaccination in March 2021 following B.1.351-variant outbreak
por: Willeit, Peter, et al.
Publicado: (2022)

Four COVID-19 Cases of New Variant B.1.351 First Emerging in South Africa in Chinese Passengers on Same Flight — Shenzhen, China, January 2021
por: Cheng, Cong, et al.
Publicado: (2021)

SARS-CoV-2 B.1.1.7 and B.1.351 Spike variants bind human ACE2 with increased affinity
por: Ramanathan, Muthukumar, et al.
Publicado: (2021)

SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity
por: Ramanathan, Muthukumar, et al.
Publicado: (2021)

Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?
por: Robertson, John F R, et al.
Publicado: (2021)

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)
por: Moyo-Gwete, Thandeka, et al.
Publicado: (2021)

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
por: Madhi, Shabir A., et al.
Publicado: (2021)

Linked transmission chains of imported SARS-CoV-2 variant B.1.351 across mainland France, January 2021
por: Calba, Clémentine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jjt5rfg6uqs9r3sq7s4cgn4311